Biocon Ltd.

Technically:

1) Volume profile when it started going up from bottom (White bars) shows clear accumulation and upmove

2) Price crossed above 50 and 200 ema. 50 crossed over 200.

3) Inverted H&S continuation almost completed.

4) Volume dry up at bottom of head and bottom of shoulders.

5) Increase in FII and DII stake. Lic bought 5 lakh shares in September from market.

Fundamentally:

Value unlock from divestment. Sold branded formulations biz to Eris Lifesciences.

USFDA clearance of Malaysia Plant.

Launch of biosimilar products and focus on increasing sales in generics.

Japanese approval for its Drugs.

It is testing out the generic version of Ozempic (the wonder drug for fat loss, insulin based) 

Sales up 20% over FY 23, EPS more than double over FY 23.

CCC down from 130 days to 55 days.

And others ......